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Left ventricular assist devices (LVADs) constitute a recent advance in heart failure (HF) therapeutics. As the rigorous experimental
assessment of LVADs in HF requires large animal models, our objective was to develop a bovine model of cardiomyopathy.
Male calves (n = 8) were used. Four animals received 1.2 mg/kg intravenous doxorubicin weekly for seven weeks and four
separate animals were studied as controls. Doxorubicin-treated animals were followed with weekly echocardiography. Target LV
dysfunction was deﬁned as an ejection fraction ≤35%. Sixty days after initiating doxorubicin, a terminal study was performed
to determine hemodynamic, histological, biochemical, and molecular parameters. All four doxorubicin-treated animals exhibited
signiﬁcant (P<0.05) contractile dysfunction, with target LV dysfunction achieved in three animals. Doxorubicin-treated hearts
exhibited signiﬁcantly reduced coronary blood ﬂow and interstitial ﬁbrosis and signiﬁcantly increased apoptosis and myocyte
size. Gene expression of atrial natriuretic factor increased more than 3-fold. Plasma norepinephrine and epinephrine levels
were signiﬁcantly increased early and late during the development of cardiomyopathy, respectively. We conclude that sequential
administration of intravenous doxorubicin in calves induces a cardiomyopathy with many phenotypic hallmarks of the failing
human heart. This clinically-relevant model may be useful for testing pathophysiologic responses to LVADs in the context of
HF.
1.Introduction
Many insights into the biological mechanisms of left ven-
tricular (LV) remodeling and heart failure (HF) have been
derived from small animals, particularly rodents such as
mice.However,establishingdirectanalogiesbetweenrodents
and humans can be problematic as there are considerable
diﬀerences in cardiac physiology (e.g., heart rate, oxygen
consumption, regulatory proteins, contractile proteins, stem
cell characteristics, etc.) between species [1]. Validation and
proper translation of fundamental discoveries into clinical
utility necessitates the use of large animal models that more
closely approximate human physiology [1, 2].
A recent advance in HF therapeutics consists of mechan-
ical unloading with LV assist devices (LVADs). A large
animal disease model that mimics the human cardiovascular
condition (bovine or ovine) [3] is particularly critical for
the rigorous evaluation of (patho)physiological responses
induced by LVADs, as phylogenetically lower species can-
not physically accommodate implantable cardiac devices.
Moreover, prolonged mechanical unloading with LVADs can
reverse remodeling of the human failing LV [4], with reports
of myocardial recovery suﬃcient for LVAD explantation in
as u b s e to fp a t i e n t s[ 5, 6]. Meaningful assessment of the
hemodynamic and molecular mechanisms of LVAD-induced
myocardial recovery and the inﬂuence of diﬀerent strategies2 Journal of Biomedicine and Biotechnology
of mechanical unloading requires the use of a reliable large
animal model of HF.
In view of both anatomical size of the thoracic cavity
and cardiovascular physiology, the current industry stan-
dard is to use normal calves to test safety, performance,
and reliability of LVAD systems. However, evaluation of
these devices in animals with chronic HF, with attendant
diﬀerences in cardiac physiology and hemodynamics from
the normal condition, has been extremely limited [7–9].
As myocardial recovery most often has been reported in
patients with idiopathic dilated cardiomyopathy [5], our
objective in this study was to develop a nonischemic bovine
model of cardiomyopathy to provide a substrate for studying
device-based therapies for HF. For this purpose, we used
doxorubicin, a broad-spectrum antineoplastic drug with
dose-dependent cardiotoxicity that has been used to induce
chronic HF in several animal species that include sheep
[10, 11]a n dd o g s[ 12–17].
2. Methods
2.1. Animals. All animals received humane care and were
handledinaccordancewithNationalInstitutesofHealthand
University of Louisville Animal Care Committee guidelines.
Experimental procedures followed animal study protocols
approved by the University of Louisville Institutional Animal
Care and Usage Committee.
Male Jersey and mixed-breed calves (n = 8, 4–6 months
old, 88 ± 6kg) were used. Four animals were administered
intravenous doxorubicin 1.2mg/kg once weekly via the
external jugular vein for seven weeks. One animal that
was relatively refractory to doxorubicin treatment received
a dose of 1.5mg/kg for the last two doses. For 48 hours
following each injection, animals were given 100mg oral
atenolol daily to prevent arrhythmia [19]. Four animals were
used as controls for myocardial blood ﬂow, histological,
and molecular analyses. A separate group of 9 normal, age-
matched calves from a previous study in our laboratory
[18] were used for hemodynamic comparison with the
doxorubicin group. Serial venous blood samples were drawn
from doxorubicin-treated animals at baseline, 14-day-, and
45-day-time points during the doxorubicin administration
protocol.
2.2. Echocardiography. Transthoracic M-mode, 2D, and
Doppler echocardiograms were measured at baseline and
weekly during the doxorubicin protocol with a Phillips iE33
machine with S8-3 ultrasound probe. Prior to the ﬁnal
study and termination, open-chest epicardial echocardiog-
raphy was performed. Modiﬁed parasternal and apical four-
chamber views were used for imaging, and LV ejection
fraction (EF) was determined using the modiﬁed Simpson
technique (summation of discs). Target LV dysfunction was
deﬁned as an LVEF of less than or equal to 35%.
2.3. Surgical Preparation for Hemodynamic Measurement.
Within 10 days of the ﬁnal doxorubicin injection, a terminal
study was performed to measure cardiovascular hemody-
namics and to harvest tissues for myocardial blood ﬂow,
histology, and molecular analysis. Animals were preanes-
thetized with intravenous atropine (30mg), anesthetized
with inhaled isoﬂurane (3–5%), and anticoagulated with
intravenous heparin (100units/kg). Fluid-ﬁlled arterial and
venous catheters were placed in the right carotid artery and
jugular vein for blood sampling. A left thoracotomy was per-
formed and ribs no. 4 and no. 5 were resected. High-ﬁdelity
micromanometercatheters(MillarInstruments)wereplaced
in the left atrium (single-tip) and across the aortic valve
(dual-tip) for simultaneous measurement of left atrial (LA),
LV, and aortic blood pressure. Transit-time ultrasonic ﬂow
probes (Transonics) were placed around the pulmonary
artery and left main coronary artery to measure cardiac
output and volumetric coronary blood ﬂow, respectively.
2.4. Microsphere Protocol. A silicone catheter (7 Fr; Access
Technologies) was advanced 4cm into the LA appendage
chamber. This depth and the angle of catheter entry parallel
to the surface of the atrial appendage ensured that the
catheter did not interfere with mitral valve function. An
aortic catheter oriented downstream was placed in the
aorta as previously described [20]. The LA catheter was
used for injection of multiple colors of ﬂuorescent-labeled
15μm microspheres into the systemic arterial circulation.
Simultaneously, a reference blood sample was withdrawn
at a known rate (15mL/min) from the aorta as previously
described [20].
The microsphere technique enables the precise measure-
ment of regional blood ﬂow in vascular beds of interest.
Microspheres injected into the LA chamber mix with blood
in the LV and are subsequently ejected into the aorta,
from where they disseminate throughout the body and
lodge within the smallest precapillary arterioles based on
regional tissue blood ﬂow distribution. We have previously
demonstrated that with the quantity used, 15μms p h e r e s
do not cause ischemia and do not induce pathology [20].
The aortic blood sample acts as a reference for later
determination of ﬂow in tissues of interest. The number
of counted microspheres in the reference blood sample
(known) is compared to the number of microspheres that
lodge and are counted in a tissue sample of interest (known).
The ratio between the two sphere counts is equal to the ratio
betweenthecalibratedrateofaorticwithdrawal(known)and
ﬂowinthetissueofinterest(unknown)andprovidesaccurate
tissue-speciﬁc blood ﬂow in mL/min/g [20, 21].
2.5. Quantiﬁcation of Microspheres. At the completion of
the study, while under anesthesia, euthanasia was per-
formed with a single fatal bolus injection of Beuthanasia-
D Special (1mL/5kg IV). The heart was removed and
weighed. One- to two-gram tissue sections from the LV-free
wall, right ventricular(RV)-free wall, and interventricular
septum together with reference blood samples were sent
to IMT/Stason Laboratories (Irvine, CA) for automated
digestionandcountingofﬂuorescentmicrosphereswithﬂow
cytometry and calculation of tissue-speciﬁc blood ﬂows.Journal of Biomedicine and Biotechnology 3
Table 1: Primers used for real-time PCR.
Gene Forward Primer Reverse Primer
ANF 5 -CAGGGCAAACAGGAGCAAA-3  5 -TCCATCAGGTCTGCATTGGA-3 
CTGF 5 -TCCCACGGAGGGTCAAACT-3  5 -CATCACGGGACACCCATTC-3 
MMP-2 5 -CCTGGGCCCCGTCACT-3  5 -GAGATGCCGTCGAAGACGAT-3 
MMP-9 5 -TTAGGAACCGCTTGCATTTCTT-3  5 -CCCCCTCCCTCAGAAAGTCT-3 
18s rRNA 5 -CGAACGTCTGCCCTATCAACTT-3  5 -ACCCGTGGTCACCATGGTA-3 
ANF, atrial natriuretic factor (NM 174124); CTGF, connective tissue growth factor (NM 174030); MMP-2, matrix metalloproteinase-2 (NM 174745); MMP-
9, matrix metalloproteinase-9 (NM 174744); 18s rRNA, 18s ribosomal RNA (eukaryotic sequence).
2.6. Hemodynamic Instrumentation and Data Reduction. All
pressure and ﬂow transducers were pre- and postcalibrated
against known physical standards to ensure measurement
accuracy. Data were collected at 400Hz, signal conditioned,
and A/D converted for digital analysis using our GLP
compliant data acquisition system [22]. Pressure and ﬂow
recordings were used to derive heart rate, cardiac output,
mean arterial pressure, mean LA pressure, LV peak systolic
and end-diastolic pressure (EDP), peak ±dP/dt, LV external
work, and mean diastolic coronary artery blood ﬂow. These
parameters were calculated on a beat-to-beat basis for each
30-second data set with the Hemodynamic Evaluation and
Assessment Research Tool (HEART) program developed in
Matlab (Version 6.5, MathWorks). All analyzed beats in
each data set (approximately 30–50 beats) were averaged to
obtain a single representative mean value for each calculated
parameter.
2.7. Histological Assessment. Paraﬃn-embedded tissue sec-
tions (4μm) from the LV, RV, and interventricular septum
were deparaﬃnized, rehydrated, and stained with Masson’s
Trichrome (for collagen) with standard histological tech-
niques as previously described [23]. To determine myocyte
cross-sectionalarea,FITC-conjugatedwheatgermagglutinin
(Molecular Probes) staining of cell membranes together with
DAPI (Molecular Probes) nuclear costaining was performed
as previously described [24]. Myocyte area determined from
an average of ∼100–150 cross-sectional cells with centrally
located round nuclei and the total ﬁbrotic area were assessed
using Metamorph Imaging Software.
Apoptosis in cardiac tissue was determined with the
DeadEnd Fluorometric TUNEL System (Promega), which
catalytically incorporates ﬂuorescein-12-dUTP at DNA
strand breaks as previously described [24]. All sections
were counterstained with DAPI (Molecular Probes) at a
ﬁnal concentration of 2μM. Images were viewed with
epiﬂuorescencemicroscopy(NikonTE2000)within24hours
and analyzed with Metamorph Imaging Software.
2.8. Myocardial Gene Expression. mRNA expression in the
heart was quantiﬁed by real-time polymerase chain reaction
(PCR) as previously described [23, 25]. Brieﬂy, total RNA
wasisolated fromLVtissue with TRIzolreagent (Invitrogen),
and cDNA was synthesized from 1μg RNA with the iScript
cDNA Synthesis kit (BioRad). Relative levels of mRNA
transcripts for atrial natriuretic factor (ANF), connective
tissue growth factor (CTGF), matrix metalloproteinase
(MMP)-2, and MMP-9 were quantiﬁed by real-time PCR
with the use of SYBR Green (Applied Biosystems) and
the sense/antisense primer pairs listed in Table 1.D a t a
were normalized to 18s ribosomal RNA subunit expression
using the ΔΔCT comparative method, and the values from
doxorubicin-treated hearts were expressed as a fold change
over control.
2.9. Measurement of Plasma Catecholamines. Plasma nore-
pinephrine and epinephrine levels were determined by
colorimetric quantitativecompetitive ELISAwithacommer-
cially available kit (Rocky Mountain Diagnostics) according
to the manufacturer’s instructions. Brieﬂy, the derivatized
standards, test samples, and the solid phase bound analytes
competed for a ﬁxed number of antiserum binding sites.
After washing of the free antigen and the antigen-antiserum
complexes, the antibody bound to the solid phase was
detected by a peroxidase-conjugated secondary antibody.
Quantiﬁcation of unknown samples was then extrapolated
from a reference standard curve.
2.10. Statistics. Serial echocardiographic and catecholamine
data from the same animal at diﬀerent time points during
the doxorubicin protocol were compared using one-way
ANOVA with Tukey posttest. Hemodynamic, myocardial
bloodﬂow,histological,andmolecularcomparisonsbetween
doxorubicin-treated animals and normal animals were per-
formed with an unpaired t-test. A P-value < 0.05 was
considered statistically signiﬁcant. All continuous data are
reported as mean ± standard deviation.
3. Results
3.1. Clinical Findings. All four animals developed chronic
coughing, three of four animals developed dyspnea on
exertion, and one animal developed dyspnea at rest and
severe ascites. During the duration of the study, three of
four animals lost weight and exhibited signs of chronic
dehydration.
3.2. Echocardiography. The target LVEF (≤35%) was
achievedinthreeanimals,anddiminishedheartfunctionwas
induced in the remaining animal treated with doxorubicin.4 Journal of Biomedicine and Biotechnology
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Figure 1: M-mode echocardiographic images from the same animal at baseline (a) and 60 days after initiation of weekly intravenous
doxorubicin (b).
Table 2: Serial echocardiography in doxorubicin-treated calves.
Baseline Final awake Final anesthetized
LVEDV (mL) 58 ±27 3 ±22 75 ±25
LVESV (mL) 5 ±42 4 ±14∗ 46 ±17∗#
LVEF (%) 91 ±66 4 ±23∗ 36 ±23∗#
LV, left ventricular; EDV, end-diastolic volume; ESV, end-systolic volume;
EF,ejectionfraction. ∗P<0.05versusbaseline; #P<0.05versusﬁnalawake.
n = 4.
Table 3:Hemodynamicsindoxorubicin-treatedandnormalcalves.
Normal‡ Doxorubicin treated
CO (L/min) 8.1 ± 1.2 5.8 ± 2.4∗
MAP (mmHg) 90 ± 10 70 ± 17∗
LAP (mmHg) 14 ± 61 5 ± 9
LVPSP (mmHg) 103 ± 98 8 ± 22
LVEDP (mmHg) 16 ± 61 5 ± 12
peak +dP/dt (mmHg/s) 1252 ± 407 767 ± 222∗
peak −dP/dt (mmHg/s) −2528 ± 866 −1135 ± 610∗
LVEW (mm Hg·ml) 8758 ± 2441 6001 ± 2751
CAF (mL/min) 207 ± 138 77 ± 16
CO, cardiac output; MAP, mean arterial pressure; LAP, left atrial pressure;
LV, left ventricular; PSP, peak systolic pressure; EDP, end diastolic pressure;
EW, external work; CAF, coronary artery ﬂow.
‡normal calves from [18]. ∗P<0.05 versus normal.
Representative M-Mode echocardiographic images from one
animal at baseline and 60 days after initiating doxorubicin
are shown in Figure 1. Mild LV dilitation was observed
along with a much more profound reduction in systolic
contraction and shortening fraction. Group data (n = 4)
are shown in Table 2. Doxorubicin induced mild increases
in LV end-diastolic volume (EDV) that were not statistically
signiﬁcant, but signiﬁcant (P<0.05) increases in LV
end-systolic volume (ESV) and worsening of LVEF were
observed.Theseeﬀectsweremoreprofoundunderisoﬂurane
anesthesia.InthesubsetofanimalsthatachievedtargetLVEF,
there was signiﬁcant exacerbation of all echocardiographic
parameters of interest (baseline versus ﬁnal anesthetized:
LVEDV 57 ± 2v e r s u s7 1± 29mL; LVESV 6 ± 3v e r s u s5 2±
15mL; LVEF 89 ± 6v e r s u s2 5± 10%; P<0.05).
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Figure 2: Regional myocardial blood ﬂow was determined with
15μm microspheres in control and doxorubicin-treated animals.
∗P<0.05 versus control; n = 4/group.
3.3. Hemodynamics. Table 3 depicts hemodynamic param-
eters measured 60 days after the initiation of doxorubicin.
As compared to normal calves of somewhat smaller size
(n = 9, mean weight: 76.1kg) that were previously studied
in our laboratory [18], doxorubicin-treated calves exhibited
hemodynamic changes indicative of LV contractile dysfunc-
tion with signiﬁcantly (P<0.05) decreased cardiac output,
mean arterial pressure, peak +dP/dt, and peak −dP/dt, and
a trend toward decreased LV peak systolic pressure (P =
0.10), LV external work (P = 0.10), and left main coronary
arterybloodﬂow(P = 0.12).Interestingly,despitesigniﬁcant
inotropic and lusitropic depression, ﬁlling pressures (LA
pressure and LV end-diastolic pressure) were comparable
between the groups.
3.4. Regional Myocardial Blood Flow. Figure 2 demonstrates
regional myocardial blood ﬂow in the LV-free wall, inter-
ventricular septum, RV-free wall, and the transmural distri-
bution in control animals and doxorubicin-treated animalsJournal of Biomedicine and Biotechnology 5
Control
Doxorubicin
LV Septum RV
6
5
4
3
2
1
0
F
i
b
r
o
s
i
s
a
r
e
a
(
%
)
∗
(a)
Control, 40x
(b)
Doxorubicin, 40x
(c)
Figure 3: (a) Interstitial ﬁbrosis as determined by Masson’s Trichrome staining in control and doxorubicin-treated hearts. (b) and (c)
Representative histomicrographs of myocardial architecture in control and doxorubicin-treated hearts. In control animals, the outlines of
individual myocytes are apparent. Interstitial endo- and perimysium are well established and clearly visible. In doxorubicin treated animals,
normal myocyte borders are not apparent, and connective tissue is largely absent. 40x, white bar = 50μm, ∗P<0.05 versus control. LV, left
ventricle; RV, right ventricle; n = 4/group.
at 60 days after initiation of doxorubicin. There were
statistically signiﬁcant (P<0.05) reductions in myocardial
blood ﬂow in the LV- and RV-free walls and trends toward
reduced blood ﬂow in the septum (P = 0.13), epicardium
(P = 0.07), midmyocardium (P = 0.07), and endocardium
(P = 0.13).
3.5. Histology and Gene Expression. Gross heart weights were
518 ± 82g for control animals and 604 ± 90g for animals
treated with doxorubicin and were not statistically diﬀerent
as a direct comparison (P = 0.25) or normalized to body
weight (P = 0.88) and suggest the absence of doxorubicin-
induced hypertrophy at the chamber level.
Figure 3 demonstrates the degree of collagen deposi-
tion/ﬁbrosis in the LV, RV, and interventricular septum as
determined by Masson’s Trichrome staining. As compared
to control hearts, after doxorubicin treatment, connective
tissue decreased or tended to decrease in each of the three
regions (LV P = 0.14, septum P<0.10, RV P<
0.01). Moreover, as seen in the accompanying representative
histomicrographs,theoutlineofindividualmyocytesandthe
interstitial space were well established and clearly visible in
control hearts. In contrast, doxorubicin-treated hearts did
not exhibit clear myocyte borders, and interstitial connective
tissue volume was markedly diminished. To explore this
further, we examined myocardial gene expression of CTGF,
a proﬁbrotic matrix-associated protein, and MMP-2 and -9,
which would be expected to augment collagen degradation
(Figure 4)[ 23]. As compared with control hearts, CTGF
expression was unchanged in doxorubicin-treated hearts,
whereas MMP-2 expression was signiﬁcantly (P<0.05)
upregulated. MMP-9 expression tended toward a decrease
(P = 0.09). The large increase in MMP-2 would be expected
to favor collagen turnover and loss, which was consistent
with the histological ﬁndings in Figure 3.6 Journal of Biomedicine and Biotechnology
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Figure 4: mRNA expression for atrial natriuretic factor (ANF),
connective tissue growth factor (CTGF), matrix metalloproteinase-
(MMP-) 2, and MMP-9 in control and doxorubicin-treated hearts
as quantiﬁed by real-time PCR. Individual gene expression was
normalized to 18s ribosomal RNA and displayed as a percent of
control. ∗P<0.05 versus control; n = 4/group.
Figure 5 shows representative wheat-germ agglutinin
staining of cell membranes and corresponding myocyte size
in the LV, RV, and interventricular septum from control
and doxorubicin-treated hearts. As compared with control
hearts, after doxorubicin treatment myocyte size increased in
each of the three regions and indicated pathologic myocyte
hypertrophy. This increase was statistically signiﬁcant (P<
0.05) in the RV and septum but not statistically signiﬁcant
in the LV (P = 0.29). In control hearts, myocytes were
of a uniform size and shape, and interstitial space was
clearly visible as dark, variegated bands throughout the
myocardium. In doxorubicin-treated hearts, myocytes were
hypertrophic and nonuniform in shape. Consistent with
these histological ﬁndings of hypertrophy, mRNA expression
of ANF, a hypertrophic marker, was increased ∼3.5-fold
in doxorubicin-treated hearts as compared with control
(Figure 4).
One potential explanation for doxorubicin-induced
myocytehypertrophywithoutchangesinLVchamberweight
would be the concomitant enhancement of myocardial cell
loss. Figure 6 demonstrates representative TUNEL stains
from control and doxorubicin-treated hearts and the overall
apoptotic rate in the LV, interventricular septum, and RV.
As compared to controls, doxorubicin treatment enhanced
myocardial apoptosis in the heart. This increase was sta-
tistically signiﬁcant in the left ventricle (P<0.01), of
borderline signiﬁcance in the interventricular septum (P =
0.10), and not signiﬁcant in the right ventricle (P =
0.39). Staining morphology and the proximity of cells to
vascular structures suggested that the apoptotic cells were
a mixture of myocytes, endothelial cells, and immune
cells.
3.6. Plasma Catecholamines. As shown in Figure 7, plasma
norepinephrine levels were signiﬁcantly increased 14 days
into the doxorubicin administration protocol and subse-
quently returned to baseline at 45 days. Plasma epinephrine
increased progressively during doxorubicin administration
and was signiﬁcantly increased over baseline at 45 days.
Collectively, these data indicate heightened circulating cat-
echolamines and adrenergic activation, a hallmark of car-
diomyopathy and heart failure [26].
4. Discussion
In this study, we report for the ﬁrst time a stable model
of doxorubicin-induced cardiomyopathy in the calf. Specif-
ically, weekly intravenous injections of doxorubicin induced
(1) mild LV dilatation with impaired LV contraction and
relaxation, (2) reductions in cardiac output without changes
in LV ﬁlling pressure, (3) reductions in myocardial blood
ﬂow, (4) myocyte hypertrophy, (5) cardiac cell apoptosis,
(6) loss of interstitial collagen, and (7) an increase in
plasma catecholamines. Most of these phenotypic features
are hallmarks of the failing human heart. Given that the
calf is generally used for preclinical testing of mechanical
circulatory support devices, this bovine model may be useful
as a platform for testing acute and chronic pathophysiologic
responses to LVADs in the context of HF and for the
development of adjunct therapies for myocardial recovery.
Doxorubicin is a potent broad-spectrum antineoplastic
drug with dose-dependent cardiotoxicity that clinically can
manifest as cardiomyopathy and HF [27]. Multiple patho-
logical mechanisms have been proposed for doxorubicin-
induced cardiomyopathy that include the generation of
free radicals, oxidative stress-induced lipid peroxidation
and mitochondrial damage, suppression of cardiac gene
expression and protein synthesis, augmented release of
catecholamines, and cardiomyocyte and endothelial cell
apoptosis [27–29]. The large number of mitochondria in the
heart and the strong aﬃnity of anthracyclines for the inner
mitochondrial membrane phospholipid cardiolipin con-
tribute to the mitochondrial accumulation of doxorubicin
and predispose cardiac myocytes to doxorubicin toxicity
[30].Assuch,multipleinvestigatorshaveusedanthracyclines
such as doxorubicin to induce cardiomyopathy and HF in
a variety of large animal models that include dogs and
sheep [10–17, 31]. Large animal studies that have used
sequential weekly doxorubicin doses for a circumscribed
period (as was done in our study) report a cardiomyopathy
that is progressive over the long term without evidence of
spontaneous improvement [10–13, 16].
In dogs and sheep, serial doxorubicin administration
decreased cardiac output by 15–32% [11, 12, 15, 17].
Similarly, in our bovine model, cardiac output was 28%
lower than normal animals. Moreover, signiﬁcant contractile
andlusitropicdysfunctionwasevidentwith ∼40%reduction
in peak +dP/dt and ∼55% reduction in peak –dP/dt.
Interestingly, LV dilatation, a hallmark of anthracycline
cardiotoxicity in rodents [27], was relatively modest in
our calf model, and ﬁlling pressures were normal despiteJournal of Biomedicine and Biotechnology 7
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Figure 5: (a) Myocyte area as determined by wheat germ agglutinin and DAPI costaining in control and doxorubicin-treated hearts. (b)
and (c) Representative wheat germ agglutinin and DAPI costaining in control and doxorubicin-treated hearts delineating myocyte cell
membranes (green) and nuclei (blue). In control animals, myocytes are of a uniform size and shape, and interstitial space is clearly visible
as dark, variegated bands through the myocardium. In doxorubicin-treated animals, myocytes are hypertrophic and nonuniform in shape.
20x, white bar = 100μm, ∗P<0.05 versus control. LV, left ventricle; RV, right ventricle; n = 4/group.
reduced cardiac output. This suggests that pathological
remodeling and hemodynamic decompensation may have
become more pronounced upon larger doses of doxorubicin
and/or a greater duration of followup. Alternatively, these
less pronounced phenotypic features may be species-speciﬁc
and distinguish doxorubicin-mediated responses in the calf
in comparison with other animal species.
LVEF dropped by ∼30% in the conscious state and
∼60% in the anesthetized state as compared with baseline.
Importantly, high-baseline LV ejection fraction is normal in
calves. The juvenile calf has an accelerated calcium turnover
rate and high myocardial contractility [32]. Interestingly, it is
well documented that bovine hemodynamics diﬀer between
conscious and anesthetized conditions [33, 34]. Normal
ejection fraction in calves has been reported to be as high
as 85 ± 9% in the conscious state [35]a n d6 3± 10% under
anesthetized conditions [33]. In our study, after seven weeks
of doxorubicin, the calves exhibited an ejection fraction
of 64 ± 23% in the conscious state and 36 ± 23% under
isoﬂurane anesthesia. LVEF in the conscious state may have
overestimated basal mechanical function in these animals,
as they were uniformly anxious with attendant increase in
stress-induced, catecholamine-mediated eﬀects on cardiac
performance. As a result, echocardiographic measurements
were performed in a hyperdynamic state as occurs during a
stress echocardiogram. Both echocardiographic and hemo-
dynamic measurement in the anesthetized state conﬁrmed
signiﬁcant systolic dysfunction after doxorubicin admin-
istration. Moreover, doxorubicin-treated animals exhibited
several characteristic histological, biochemical, and molecu-
lar features of pathological cardiac remodeling and myocyte
hypertrophy.8 Journal of Biomedicine and Biotechnology
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Figure 6: (a) Myocardial apoptotic rate determined with TUNEL staining in control and doxorubicin-treated hearts. (b) and (c)
Representative TUNEL staining (with DAPI costaining) in control and doxorubicin-treated hearts. Nuclei are stained blue. TUNEL positive
nuclei are green/cyan. 10x, white bar = 200μm, ∗P<0.05 versus control. LV, left ventricle; RV, right ventricle; n = 4/group.
Myocardial apoptosis and microvascular insuﬃciency
both contribute to myocardial dysfunction in anthracycline-
induced HF [27–29, 36]. Indeed, doxorubicin-treated bovine
hearts in our study exhibited both a 5 to 6-fold increase in
apoptotic rate and profound reductions in myocardial blood
ﬂow as quantiﬁed by regional microsphere distribution. As
prior work has demonstrated that doxorubicin can induce
apoptosis of cardiomyocytes and endothelial cells [25–27],
these two phenomena may be interrelated. Speciﬁcally,
endothelial cell death in the microvasculature may have
contributed to the observed reductions in coronary blood
ﬂow. Indeed, we frequently observed foci of apoptotic nuclei
in proximity to or within coronary arterioles in the heart,
which suggests that at least some apoptotic cells were of
vascular or endothelial origin.
As cardiomyopathic hearts generally show augmented
interstitial ﬁbrosis and collagen deposition [37], our ﬁnding
of reduced interstitial collagen volume in doxorubicin-
treated hearts was surprising. However, prior work has
demonstrated that doxorubicin upregulates and activates
matrix metalloproteinases in the heart [38] and can also
inhibit collagen synthesis [39] (both of which would favor
collagen degradation). Indeed, in our study, the expression
of proﬁbrotic CTGF in the heart was not aﬀected by
doxorubicin, whereas MMP-2 (which promotes collagen
breakdown) was upregulated, consistent with these prior
observations. In a rat study of the cardiac matrix following
a single injection of doxorubicin, a biphasic course of
myocardial remodeling was observed. The initial response
(up to 6 weeks after injection) was loss of the myocardial
collagen matrix. At later time points, abnormal deposition
of collagen produced focal myocardial scarring [40]. Hence,
the interstitial remodeling after doxorubicin exposure may
not be uniform and may depend on the stage of progres-
sion of doxorubicin-induced ventricular remodeling. It is
possible that in our animals, longer periods of treatment
or followup may have augmented collagen deposition, and
greater ﬁbrosis may have been observed. Moreover, asJournal of Biomedicine and Biotechnology 9
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Figure 7: Plasma norepinephrine and epinephrine levels measured
at the indicated time points during doxorubicin administration in
calves. ∗P<0.05 versus baseline; n = 4/group.
myocardial ﬁbrosis increases, ventricular chamber stiﬀness
increases. The reduced collagen deposition that we observed
may underlie the absence of diastolic ﬁlling pressure
elevation in doxorubicin-treated hearts. The decrease in
matrix protein may have increased chamber compliance
and thereby maintained LVEDP at levels comparable to
normal animals, despite the development of doxorubicin
cardiomyopathy. The depressed peak dP/dt and cardiac
output in doxorubicin-treated animals despite equivalent
LVEDP (preload) indicated signiﬁcant contractile dysfunc-
tion in these animals. Filling pressure elevation and further
hemodynamic compensation would have likely occurred
over longer time periods that allowed for further progression
of pathological remodeling.
4.1. Limitations. Our results must be interpreted in light of
potential study limitations. In our study, the calves exhibited
variability of response to doxorubicin toxicity. The one
animal that was somewhat resistant to doxorubicin was a
pure-breed Jersey calf, whereas the other three animals were
mixed breed. Response variability has also been reported
in other studies with doxorubicin. Astra et al. reported in
a canine model of doxorubicin cardiomyopathy that one
animal in their medium dose cohort showed no cardiac
impairment, whereas all others animals showed severe
impairment or died of heart failure [16]. Another study
limitation was the small number of experimental animals,
a situation that was mandated by unanticipated limitations
in available resources for large animal maintenance. The
small sample size increased the risk of type I statistical error
(i.e., that the observed eﬀects may have been driven by
chance ﬁndings in just one animal) and type II statistical
error (i.e., ﬁnding no diﬀerence between groups due to a
small number of observations when a diﬀerence truly exists).
Nonetheless, despite the study of only four animals, the
observed hemodynamic, structural, histological, biochemi-
cal, and molecular changes were all suﬃciently robust to
establish the induction of LV dysfunction and pathological
remodeling by doxorubicin. Moreover, the observed changes
were consistent with multiple prior studies of doxorubicin-
induced cardiomyopathy in other animal models (described
above),suggestthatourresultswereexperimentallyvalidand
not simply the result of chance statistical variation.
These limitations notwithstanding, our results establish
the validity and feasibility of a clinically relevant bovine
model of doxorubicin-induced cardiomyopathy that shares
many phenotypic similarities with human heart failure.
This model may prove useful assess the pathophysiological
responses to LVADs and associated adjunctive therapies in
HF.
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